Role of Ormeloxifene (SERM) in Treatment of Fibrocystic Breast Disease in patients aged 18-50 years in a tertiary care hospital in Chennai.

Abstract

BACKGROUND AND OBJECTIVE: The most prevailing clinical problem that drives women to the surgical outpatient department is mastalgia, or breast soreness. It's captious to fully grok the problem's epidemiological, pathological, and radiological aspects. The intention of this study, which took place at a tertiary care centre  in Chennai, was to see how well ormeloxifene worked in female patients aged 18 to 50  who had breast pain from fibrocystic breast disease or not.

 METHODOLOGY: 69 patients were selected consecutively based on inclusion and exclusion criteria. Mastalgia is diagnosed based on a history of breast discomfort lasting more than 10 days per cycle, followed by a USG B/L breast to confirm the existence of fibrocystic breast disease. Patients who used Tab Ormeloxifene 30mg every alternate day per week for three months were evaluated for follow-up at months one, two, three, and six. Breast nodularity was assessed using the Lucknow-Cardiff Scale.

 RESULTS: Decrease in breast nodularity.

CONCLUSION: Fibrocystic breast disease has been proven to respond well to ormeloxifene.